News

Senhwa Biosciences Shines at G4thering 2025, Reinforcing Global Leadership and Driving International Cooperation

The 9th International G4 Conference (G-Quadruplex, G4thering 2025) is being held from June 2 to 5 in Minneapolis, the largest city in Minnesota, USA, bringing together leading voices in G-quadruplex (G4) research. As the biotech company conducting clinical trials of Pidnarulex (CX-5461), its first-in-class G4 stabilizing agent for cancer treatment, Senhwa’s presence at this forum is a testament to its continued leadership in clinical G4 research. Represented by Acting CEO and Chief Medical Officer Dr. Ping-Yen Huang and Pre-clinical Research Lead Dr. Kai-Wei Hsueh, the company is actively engaging with leading global scientists and industry executives to explore cutting-edge research and future applications of G4 structures in gene regulation, cancer treatment, and innovative drug development. Senhwa’ achievements in G4-targeted therapeutics have drawn significant attention from the global biotech community, solidifying its leadership in the field and catalyzing new opportunities for future international collaboration.

Acting CEO and Chief Medical Officer Dr. Ping-Yen Huang (left), Pre-clinical Research Lead Dr. Kai-Wei Hsueh (right)

CX-5461 is the first-in-class G4 stabilizer, selectively targeting and stabilizing G-quadruplex structures to inhibit their unwinding. This induces replication-dependent DNA damage, ultimately leading to cancer cell apoptosis. G-quadruplex structures are particularly enriched in tumor tissues, especially in transcriptionally active genes, indicating a functional role in cancer progression. CX-5461’s ability to precisely target G4 structures and induce DNA damage in cancer cells makes it a promising drug candidate for various cancers, particularly in the treatment of relapsed or refractory hematologic malignancies and solid tumors. “We are committed to translating the therapeutic potential of G4 structures into innovative cancer treatments. The clinical advancement of CX-5461 reflects both the depth of our R&D expertise and Taiwan’s strength on the global stage of new drug development,” said Dr. Ping-Yen Huang at G4thering 2025. 

CX-5461 continues to gain international recognition for its novel mechanism and broad-spectrum antineoplastic potential. Recently, it was selected by the U.S. National Cancer Institute (NCI) for inclusion in the NExT (NCI Experimental Therapeutics) Program, which will fund five years of clinical development, including four planned human trials. The program will also explore CX-5461’s combination with cutting-edge immunotherapies to accelerate its development and market launch. Other accolades include an award from Canada’s Stand Up to Cancer (SU2C) Dream Team Drug for breast cancer, as well as selection for a human clinical trial in prostate cancer in combination with Pfizer’s marketed PARP inhibitor. Moreover, at the recently concluded AACR Annual Meeting, several leading global cancer research teams presented promising results using CX-5461 in treating triple-negative breast cancer, high-grade serous ovarian cancer, and ADAR1-overexpressing tumors. These developments underscore CX-5461’s substantial commercial potential, driven by both its mechanistic innovation and applicability in oncology.

Additionally, CX-5461 has shown potential to activate immune cells and transform the tumor microenvironment, enhancing responses to immunotherapy. Under the leadership of the NCI, upcoming clinical trials will explore the combination of CX-5461 with immunotherapeutics, with the goal of expanding the population that can benefit from immunotherapy.

Held biennially since 2007, the G4thering has evolved into a hub for global research and application of G4 structures. The successful execution of this year’s conference has further propelled international collaboration and innovation in the G4 space.
For more information, please visit the official website: https://g4society.org/